GCP ClinPlus offers end-to-end infectious disease clinical trials solutions across the full spectrum of anti-infective therapies, including vaccines, antivirals, and antibiotics. With over 23 years of focused experience and a proven pandemic response framework, we help sponsors accelerate development with speed, quality, and regulatory confidence. Our programs align with WHO prequalification standards and have supported major global trials—such as a Phase III, multi-country COVID-19 vaccine study.
Delivering What Matters to Biopharma
GCP ClinPlus is a leading Infectious Disease CRO in China in anti-infective research, offering agile, full-lifecycle clinical development services that accelerate time to market for vaccines, antivirals, antibiotics, and antiparasitic agents.
Delivering What Matters to Biopharma
We have successfully supported nearly 100 anti-infection clinical projects, including INDs, NDAs, and global multicenter trials across early and late development stages.
Our expertise spans a wide range of agents, including:
Antibiotics (e.g., carbapenems, cephalosporins, tetracyclines, macrolides)
Antivirals and vaccines, including pandemic-response products
Antifungals, antituberculosis drugs, and antiparasitic agents
Our anti-infection clinical service model includes:
WHO-aligned clinical strategies and regulatory documentation
Flexible trial designs and rapid-response operational frameworks
Accelerated project timelines, even under high-pressure outbreak conditions
Experienced clinical teams providing continuous scientific and regulatory support
Whether you're launching a novel antiviral, preparing for WHO PQ submission, or scaling a vaccine trial globally, GCP ClinPlus delivers the infrastructure, expertise, and urgency to bring your anti-infective innovations to patients faster and safer.
For more information about infectious disease clinical research and Vaccine CRO in China, please feel free to contact us!
There are many clinical trial research companies, but we are the best choice for you.
